ERS Genomics and IRBM sign CRISPR/Cas9 license agreement news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
ERS Genomics Limited (?ERS'), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS' CRISPR/Cas9 patent portfolio..
License agreement provides IRBM access to CRISPR gene editing technology to be applied across its drug discovery services offering ERS Genomics Limited ('ERS'), the CRISPR licensing Company, and IRBM